Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.84M | -79.53M | -93.44M | -97.61M | -101.39M |
| Total Depreciation and Amortization | 445.00K | 463.00K | 471.00K | 405.00K | 298.00K |
| Total Amortization of Deferred Charges | 0.00 | 140.00K | 140.00K | 140.00K | 140.00K |
| Total Other Non-Cash Items | 4.49M | 28.76M | 29.16M | 27.88M | 27.18M |
| Change in Net Operating Assets | -9.11M | -6.23M | -6.35M | -8.53M | -1.83M |
| Cash from Operations | -43.01M | -56.40M | -70.01M | -77.72M | -75.61M |
| Capital Expenditure | -13.00K | -189.00K | -2.34M | -3.18M | -3.28M |
| Sale of Property, Plant, and Equipment | 18.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.27M | 72.64M | 82.64M | 53.00M | 29.97M |
| Cash from Investing | 36.27M | 72.45M | 80.31M | 49.82M | 26.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.00M | 9.00K | 8.82M | 28.06M | 28.07M |
| Repurchase of Common Stock | -1.00K | -1.00K | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -381.00K | -121.00K | -290.00K | -612.00K | -1.01M |
| Cash from Financing | 4.62M | -113.00K | 8.53M | 27.45M | 27.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.12M | 15.94M | 18.83M | -450.00K | -21.86M |